Neurocrine Biosciences Q4 2025 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy NBIX?
Source: seekingalpha
- Significant Growth: In 2025, Neurocrine Biosciences reported total product sales exceeding $2.8 billion, representing a 22% year-over-year increase, with INGREZZA generating over $2.5 billion in revenue, up 9%, indicating strong market demand and effective sales strategies.
- Strong CRENESSITY Launch: CRENESSITY achieved over $300 million in net sales in its first year on the market, covering over 10% of the classic adrenal hyperplasia patient population, demonstrating the company's success in product introduction and market acceptance.
- Optimistic Outlook: Management projects INGREZZA sales to range between $2.7 billion and $2.8 billion in 2026, anticipating approximately 10% growth, reflecting confidence in future market potential and ongoing investment strategies.
- Robust Cash Flow: By the end of 2025, the company's cash reserves increased to $2.5 billion, up $700 million from $1.8 billion at the end of 2024, showcasing strong operational performance and a healthy financial position that supports future R&D and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBIX
Wall Street analysts forecast NBIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBIX is 179.68 USD with a low forecast of 143.00 USD and a high forecast of 203.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 137.650
Low
143.00
Averages
179.68
High
203.00
Current: 137.650
Low
143.00
Averages
179.68
High
203.00
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neurocrine Biosciences Q4 2025 Earnings Call Highlights
- Significant Growth: In 2025, Neurocrine Biosciences reported total product sales exceeding $2.8 billion, representing a 22% year-over-year increase, with INGREZZA generating over $2.5 billion in revenue, up 9%, indicating strong market demand and effective sales strategies.
- Strong CRENESSITY Launch: CRENESSITY achieved over $300 million in net sales in its first year on the market, covering over 10% of the classic adrenal hyperplasia patient population, demonstrating the company's success in product introduction and market acceptance.
- Optimistic Outlook: Management projects INGREZZA sales to range between $2.7 billion and $2.8 billion in 2026, anticipating approximately 10% growth, reflecting confidence in future market potential and ongoing investment strategies.
- Robust Cash Flow: By the end of 2025, the company's cash reserves increased to $2.5 billion, up $700 million from $1.8 billion at the end of 2024, showcasing strong operational performance and a healthy financial position that supports future R&D and market expansion.
See More
Neurocrine Biosciences Q4 Earnings Analysis
- Earnings Performance: Neurocrine Biosciences reported a Q4 non-GAAP EPS of $1.88, missing expectations by $0.42, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $805.5 million, a 28.3% year-over-year increase, exceeding market expectations by $16.2 million, reflecting strong sales of its core products that boosted overall performance.
- 2026 Financial Guidance: The company projects INGREZZA net product sales between $2.7 billion and $2.8 billion, with GAAP R&D expenses expected to be between $1.2 billion and $1.25 billion, highlighting its commitment to future R&D investments aimed at driving new drug development.
- R&D Expenditure: Non-GAAP R&D expenses are projected to be between $1.11 billion and $1.16 billion, with both GAAP and non-GAAP IPR&D at $20 million, indicating ongoing investment in R&D despite profitability pressures.
See More
Neurocrine Biosciences Reports Strong 2025 Financial Results
- Sales Performance Growth: Neurocrine reported fourth-quarter and full-year 2025 net product sales of $798.3 million and $2.83 billion, reflecting year-over-year growth of 29% and 22%, respectively, which underscores the company's robust market demand and sales capabilities, solidifying its position in the biopharmaceutical industry.
- INGREZZA Sales Performance: For INGREZZA, net product sales in the fourth quarter and full year of 2025 were $657.5 million and $2.51 billion, with year-over-year growth of 7% and 9%, respectively, demonstrating strong prescription volume growth driven by patient demand, despite the impact of new formulary access investments.
- CRENESSITY Market Expansion: CRENESSITY achieved net product sales of $135.3 million and $301.2 million in the fourth quarter and full year of 2025, respectively, with 431 and 2,048 new patient enrollment forms, indicating over 80% reimbursement coverage, reflecting increasing market acceptance and demand.
- R&D Pipeline Progress: The company is set to advance multiple clinical projects, including osavampator and direclidine, in 2026, which are expected to provide innovative treatment options for patients while creating long-term value for the company, further enhancing its competitiveness in the neuropsychiatry drug sector.
See More
Neurocrine Biosciences Q4 Earnings Announcement Scheduled
- Earnings Release Date: Neurocrine Biosciences (NBIX) is set to announce its Q4 earnings on February 11th after market close, with a consensus EPS estimate of $2.30, reflecting a 36.1% year-over-year growth, indicating ongoing profitability potential.
- Revenue Expectations: The anticipated revenue for Q4 is $789.3 million, representing a 25.7% year-over-year increase, which underscores the company's positive advancements in neurology and obesity R&D programs amid rising market demand.
- Historical Performance Review: Over the past two years, NBIX has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating stability in financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 10 downward revisions, while revenue estimates have experienced 2 upward revisions and 17 downward revisions, reflecting analyst divergence and market uncertainty regarding the company's future performance.
See More
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
- Clinical Trial Launch: Neurocrine Biosciences has announced the initiation of its Phase 2 clinical study for NBI-1065890, aiming to enroll approximately 100 adults with tardive dyskinesia to assess the drug's efficacy, safety, and tolerability, marking a strategic advancement in VMAT2 biology.
- Drug Characteristics: NBI-1065890 is a next-generation selective VMAT2 inhibitor with distinct physical and chemical properties that may provide treatment options for a broader range of tardive dyskinesia patients, reflecting the company's deep expertise and innovative capabilities in neuroscience.
- Efficacy Assessment Metrics: The primary efficacy endpoint of the study is the change from baseline in the AIMS score at Week 8, aiming to scientifically validate the clinical application potential of NBI-1065890, thereby delivering lasting positive impacts for patients.
- Market Outlook: Tardive dyskinesia affects at least 800,000 adults in the U.S., and the successful development of NBI-1065890 will further solidify Neurocrine's leadership position in the treatment of neuropsychiatric disorders, providing strong support for the company's future growth.
See More
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
- Clinical Trial Launch: Neurocrine Biosciences has announced the initiation of its Phase 2 clinical study for NBI-1065890, planning to enroll approximately 100 adults with tardive dyskinesia to assess the drug's efficacy, safety, and tolerability.
- Drug Characteristics: NBI-1065890 is a selective VMAT2 inhibitor with distinct physical and chemical properties, potentially offering treatment options for a broader range of tardive dyskinesia patients, reflecting nearly 20 years of expertise in VMAT2 inhibition.
- Efficacy Assessment Metrics: The primary efficacy endpoint of the study is the change from baseline in the AIMS score at Week 8, aiming to scientifically validate the clinical value of the drug and enhance its market potential.
- Strategic Importance: Advancing this clinical trial is a key component of Neurocrine's strategy to define the future of VMAT2 biology and deliver lasting therapeutic impacts for patients, further solidifying its leadership position in the neuroscience field.
See More
Neurocrine Biosciences Q4 2025 Earnings Call Highlights
- Significant Growth: In 2025, Neurocrine Biosciences reported total product sales exceeding $2.8 billion, representing a 22% year-over-year increase, with INGREZZA generating over $2.5 billion in revenue, up 9%, indicating strong market demand and effective sales strategies.
- Strong CRENESSITY Launch: CRENESSITY achieved over $300 million in net sales in its first year on the market, covering over 10% of the classic adrenal hyperplasia patient population, demonstrating the company's success in product introduction and market acceptance.
- Optimistic Outlook: Management projects INGREZZA sales to range between $2.7 billion and $2.8 billion in 2026, anticipating approximately 10% growth, reflecting confidence in future market potential and ongoing investment strategies.
- Robust Cash Flow: By the end of 2025, the company's cash reserves increased to $2.5 billion, up $700 million from $1.8 billion at the end of 2024, showcasing strong operational performance and a healthy financial position that supports future R&D and market expansion.
See More
Neurocrine Biosciences Q4 Earnings Analysis
- Earnings Performance: Neurocrine Biosciences reported a Q4 non-GAAP EPS of $1.88, missing expectations by $0.42, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $805.5 million, a 28.3% year-over-year increase, exceeding market expectations by $16.2 million, reflecting strong sales of its core products that boosted overall performance.
- 2026 Financial Guidance: The company projects INGREZZA net product sales between $2.7 billion and $2.8 billion, with GAAP R&D expenses expected to be between $1.2 billion and $1.25 billion, highlighting its commitment to future R&D investments aimed at driving new drug development.
- R&D Expenditure: Non-GAAP R&D expenses are projected to be between $1.11 billion and $1.16 billion, with both GAAP and non-GAAP IPR&D at $20 million, indicating ongoing investment in R&D despite profitability pressures.
See More
Neurocrine Biosciences Reports Strong 2025 Financial Results
- Sales Performance Growth: Neurocrine reported fourth-quarter and full-year 2025 net product sales of $798.3 million and $2.83 billion, reflecting year-over-year growth of 29% and 22%, respectively, which underscores the company's robust market demand and sales capabilities, solidifying its position in the biopharmaceutical industry.
- INGREZZA Sales Performance: For INGREZZA, net product sales in the fourth quarter and full year of 2025 were $657.5 million and $2.51 billion, with year-over-year growth of 7% and 9%, respectively, demonstrating strong prescription volume growth driven by patient demand, despite the impact of new formulary access investments.
- CRENESSITY Market Expansion: CRENESSITY achieved net product sales of $135.3 million and $301.2 million in the fourth quarter and full year of 2025, respectively, with 431 and 2,048 new patient enrollment forms, indicating over 80% reimbursement coverage, reflecting increasing market acceptance and demand.
- R&D Pipeline Progress: The company is set to advance multiple clinical projects, including osavampator and direclidine, in 2026, which are expected to provide innovative treatment options for patients while creating long-term value for the company, further enhancing its competitiveness in the neuropsychiatry drug sector.
See More
Neurocrine Biosciences Q4 Earnings Announcement Scheduled
- Earnings Release Date: Neurocrine Biosciences (NBIX) is set to announce its Q4 earnings on February 11th after market close, with a consensus EPS estimate of $2.30, reflecting a 36.1% year-over-year growth, indicating ongoing profitability potential.
- Revenue Expectations: The anticipated revenue for Q4 is $789.3 million, representing a 25.7% year-over-year increase, which underscores the company's positive advancements in neurology and obesity R&D programs amid rising market demand.
- Historical Performance Review: Over the past two years, NBIX has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating stability in financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 10 downward revisions, while revenue estimates have experienced 2 upward revisions and 17 downward revisions, reflecting analyst divergence and market uncertainty regarding the company's future performance.
See More
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
- Clinical Trial Launch: Neurocrine Biosciences has announced the initiation of its Phase 2 clinical study for NBI-1065890, aiming to enroll approximately 100 adults with tardive dyskinesia to assess the drug's efficacy, safety, and tolerability, marking a strategic advancement in VMAT2 biology.
- Drug Characteristics: NBI-1065890 is a next-generation selective VMAT2 inhibitor with distinct physical and chemical properties that may provide treatment options for a broader range of tardive dyskinesia patients, reflecting the company's deep expertise and innovative capabilities in neuroscience.
- Efficacy Assessment Metrics: The primary efficacy endpoint of the study is the change from baseline in the AIMS score at Week 8, aiming to scientifically validate the clinical application potential of NBI-1065890, thereby delivering lasting positive impacts for patients.
- Market Outlook: Tardive dyskinesia affects at least 800,000 adults in the U.S., and the successful development of NBI-1065890 will further solidify Neurocrine's leadership position in the treatment of neuropsychiatric disorders, providing strong support for the company's future growth.
See More
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
- Clinical Trial Launch: Neurocrine Biosciences has announced the initiation of its Phase 2 clinical study for NBI-1065890, planning to enroll approximately 100 adults with tardive dyskinesia to assess the drug's efficacy, safety, and tolerability.
- Drug Characteristics: NBI-1065890 is a selective VMAT2 inhibitor with distinct physical and chemical properties, potentially offering treatment options for a broader range of tardive dyskinesia patients, reflecting nearly 20 years of expertise in VMAT2 inhibition.
- Efficacy Assessment Metrics: The primary efficacy endpoint of the study is the change from baseline in the AIMS score at Week 8, aiming to scientifically validate the clinical value of the drug and enhance its market potential.
- Strategic Importance: Advancing this clinical trial is a key component of Neurocrine's strategy to define the future of VMAT2 biology and deliver lasting therapeutic impacts for patients, further solidifying its leadership position in the neuroscience field.
See More
